Growth and Long-Term Outlook for CMO II Deficiency

While the first few months after a diagnosis of CMO II deficiency are often focused on stabilizing your baby, the long-term outlook for this condition is generally very positive. With appropriate monitoring and care, children with CMO II grow up to lead healthy, active lives ^[1][2]. One of the most unique aspects of this condition is that your child’s need for medication may change significantly as they age ^[1].

Why Requirements Change with Age

It may seem surprising that a genetic condition could “improve” over time, but in CMO II, this change is largely due to physiological adaptation ^[1].

As your child grows, several things happen:

• Kidney Maturation: An infant’s kidneys are naturally less efficient at “holding onto” salt than an older child’s or adult’s kidneys ^[1][2].
• Dietary Salt: As children move from breast milk or formula to solid foods, they naturally ingest more salt ^[1].
• Body Compensation: The body finds alternative ways to maintain salt balance, even if the primary aldosterone pathway remains impaired ^[3].

In one specific clinical study of 16 children, about 30% were eventually able to discontinue fludrocortisone at a median age of 6 years old ^[1]. However, every child is different. The ability to lower or stop medication depends on residual enzyme activity, genetics, and diet. Some children require ongoing treatment indefinitely ^[2]. Any reduction in medication must be conducted as a carefully supervised trial directed by your endocrinologist. Never attempt to wean your child off medication independently.

Monitoring Growth and Development

Growth is one of the best indicators that CMO II is being managed well.

• Regular Check-ups: Your pediatric endocrinologist will track your child’s height and weight on a growth chart at every visit to ensure they are meeting their milestones ^[4][1].
• Laboratory Targets: Doctors will regularly check blood levels of sodium, potassium, and renin ^[5][2].
• Blood Pressure: Because fludrocortisone and salt affect blood volume, your team will closely monitor blood pressure to ensure the medication dose is not too high (which can cause hypertension) or too low ^[5][6].

Why Long-Term Surveillance is Essential

Even if your child is successfully weaned off daily medication, they are not “cured” of CMO II deficiency. The underlying genetic variant in the CYP11B2 gene remains ^[1].

Continued follow-up is necessary for several reasons:

• Incomplete Remission: Even when salt levels look normal in the blood, specialized tests often show that the body is still struggling slightly to make aldosterone ^[1].
• Puberty and Growth Spurts: Rapid growth can sometimes change fluid volume requirements and “unmask” a salt deficiency that was previously under control ^[1].

Quality of Life and Self-Management

Children with CMO II deficiency can participate in sports, go to camp, and travel just like their peers. The key is preparation. During periods of extreme heat, illness, or intense physical activity, their bodies may struggle to retain sodium.

Work with your endocrinologist to create a written heat and exercise plan. This plan will detail exactly what fluids or electrolyte replacements are safe and necessary. Do not independently administer “extra” fludrocortisone or unmeasured salt.

As they transition into adolescence and adulthood, they will gradually take over the management of their own health. Understanding their “salt-wasting” history allows them to advocate for themselves, stay properly hydrated, and ensure they remain protected during times of physical stress ^[1][7].